LRRC30: A Protein Expressed in Various Tissues and Potential Drug Target

Target Name: LRRC30

NCBI ID: G339291

LRRC30

Other Name(s): leucine rich repeat containing 30 | LRC30_HUMAN | leucine-rich repeat-containing protein 30 | Leucine rich repeat containing 30 | Leucine-rich repeat-containing protein 30

LRRC30: A Protein Expressed in Various Tissues and Potential Drug Target

LRRC30, also known as leucine rich repeat containing 30, is a protein that is expressed in various tissues throughout the body. It is a repeat of the leucine rich repeat gene, which is known for its role in the regulation of protein function and stability. LRRC30 has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, LRRC30 has potential as a drug target or biomarker.

The discovery and characterization of LRRC30 began in the late 1990s, when researchers identified a highly conserved region of DNA that was repeated in multiple organisms. The region contained multiple leucine rich repeats, which are known for their role in the regulation of protein function and stability. These repeats were identified as LRRC30, and the gene was named based on its repetitive structure.

LRRC30 is a transmembrane protein that is expressed in various tissues throughout the body, including muscle, nerve, heart, and brain. It is primarily localized to the endoplasmic reticulum, where it can interact with various signaling molecules and play a role in the regulation of protein function and stability.

LRRC30 has been shown to play a role in the development and progression of various diseases. For example, LRRC30 has been shown to be overexpressed in various tissues and organisms that are susceptible to cancer, including breast, ovarian, and prostate cancer. It has also been shown to be involved in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

In addition to its potential role in disease, LRRC30 has also been shown to be a potential drug target. LRRC30 can interact with various signaling molecules, including TGF-β1, which is a key regulator of cell growth and differentiation. By interacting with TGF-β1, LRRC30 has been shown to play a role in the regulation of cellular processes that are important for disease development.

LRRC30 has also been shown to be involved in the regulation of protein stability and function. It has been shown to interact with various proteinases, including trypsin and chymotrypsin, which are involved in the degradation of proteins. By interacting with these enzymes, LRRC30 has been shown to play a role in the regulation of protein stability and function, which may be important for disease development.

In conclusion, LRRC30 is a protein that has been shown to play a role in the development and progression of various diseases. Its potential as a drug target or biomarker makes it an attractive target for further research and development. Further studies are needed to fully understand the role of LRRC30 in disease and to develop effective therapies based on its unique properties.

Protein Name: Leucine Rich Repeat Containing 30

The "LRRC30 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LRRC30 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets